Information

Related Research Units

Intellectual and Developmental Disabilities Research Center Research
Neurology Research

Research Overview

 Dr. Ullrich is a dedicated onco-neurologist with an active practice at both Children’s Hospital Boston and Dana-Farber Cancer Institute, caring for children while they are on active therapy and also for many years after they complete treatment. She has completed several clinical studies evaluating risk factors for neurologic late effects of cancer and for the neuro-oncological aspects of neurofibromatosis type 1 (NF1). Currently, Dr. Ullrich is Principal Investigator for the first clinical trial through Children’s Oncology Group to attempt to remediate cognitive difficulties in children and adolescents treated for a primary brain tumor. She is also Principal Investigator of the multicenter Neurofibromatosis Clinical Trials Consortium that has now opened 3 of 4 planned clinical trials as interventions for complications of NF1, including studies of plexiform neurofibromas, brain tumors and cognitive difficulties. In addition, Dr. Ullrich has helped to develop and is working to validate a novel outcome parameter that will be used to assess spatial learning in children with NF1 as part of the current cognitive intervention trial. Dr. Ullrich’s primary focus is on her research for the Neurofibromatosis Clinical Trials Consortium at Children’s Hospital Boston, one of nine sites in the United States funded by the Department of Defense. The goal of the Consortium is to develop novel therapies for patients with neurofibromatosis type 1 (NF1), and Dr. Ullrich serves as the Site PI for three clinical trials currently taking place. The first is a Phase II clinical trial of rapamycin for progressive plexiform neurofibromas. The second, Lovastatin for Learning Deficits in Children with NF1, is a randomized clinical trial of lovastatin to reverse attention and spatial working memory deficits in children with NF1. The third is a randomized Phase II clinical trial of RAD001 (Everolimus) to treat chemotherapy-refractory brain tumors in children with NF1. In addition to these projects, Dr. Ullrich is Co-Investigator for a Phase II trial of Lonafarnib, Pravastatin and zoledronic acid in progeria. This project is a clinical trial for children with Hutchinson Guilford Progeria Syndrome (HGPS) and is funded by the NIH. Dr. Ullrich is also the study chair for an upcoming clinical trial using modafinil to improve cognitive deficits in pediatric brain tumor survivors through the Children’s Oncology Group.

 

Research Background

Dr. Ullrich received her MD from Yale University School of Medicine. She completed her internship and residency in pediatrics, as well as a residency in child neurology, at Children’s Hospital Boston. Her fellowships in neurology, neurologic neuro-oncology, and clinical investigation were completed at Children’s Hospital Boston, Dana-Farber Cancer Institute, and Harvard Medical School/Massachusetts Institute of Technology, respectively. She has received a number of awards, including the Clinical Investigator Training Program Award from Harvard University/Massachusetts Institute of Technology, the Harvard Leadership Program for Physicians and Scientists award from Harvard Medical School, and the Friend of the Brain award from Children’s Hospital Boston/Brigham and Women’s Hospital Departments of Neurosurgery. She was nominated for a Bridging Boundaries Clinical Faculty Award through Dana-Farber Cancer Institute to recognize a clinician in the subspecialties who interacts with other disciplines. Dr. Ullrich is an active member of the Clinical Care Advisory Board of the Children’s Tumor Foundation and serves as co-Chair of the Clinical Research Award. She serves as Chair of the Children’s Oncology Group Central Nervous System Late Effects committee.

 

Education

Undergraduate School

Brown University
1990 Providence RI

Graduate School

Yale University
1997 New Haven CT

Medical School

Yale University School of Medicine
1990 New Haven CT

Internship

Boston Children's Hospital
1999 Boston MA

Residency

Pediatrics Boston Combined Residency Program (BCRP)
2002 Boston MA

Fellowship

Boston Children's Hospital
2003 Boston MA

Publications

  1. Incidence of Hearing Loss in Patients With Neurofibromatosis Type 1 at a Tertiary Care Pediatric Hospital. Pediatr Neurol. 2024 Oct; 159:35-40. View Abstract
  2. Severe steroid-related neuropsychiatric symptoms during paediatric acute lymphoblastic leukaemia therapy-An observational Ponte di Legno Toxicity Working Group Study. Br J Haematol. 2024 Oct; 205(4):1450-1459. View Abstract
  3. The long-term impact of cerebellar tumor resection on executive functioning, anxiety, and fear of pain: A mixed methodology pilot study. Appl Neuropsychol Child. 2024 Apr 11; 1-11. View Abstract
  4. Discontinuation of Antiseizure Medications in Patients With Brain Tumors. Neurology. 2024 Feb 27; 102(4):e209163. View Abstract
  5. The Relationship Between Choroidal Abnormalities and Visual Outcomes in Pediatric Patients With NF1-Associated Optic Pathway Gliomas. J Neuroophthalmol. 2024 Mar 01; 44(1):5-9. View Abstract
  6. Neurologic morbidity and functional independence in adult survivors of childhood cancer. Ann Clin Transl Neurol. 2024 02; 11(2):291-301. View Abstract
  7. Cerebral Vasculopathy in Children with Neurofibromatosis Type 1. Cancers (Basel). 2023 Oct 23; 15(20). View Abstract
  8. Potential endpoints for assessment of bone health in persons with neurofibromatosis type 1. Clin Trials. 2024 02; 21(1):29-39. View Abstract
  9. Multicenter, prospective, phase II study of maintenance bevacizumab for children and adults with NF2-related schwannomatosis and progressive vestibular schwannoma. Neuro Oncol. 2023 08 03; 25(8):1498-1506. View Abstract
  10. Children's Oncology Group's 2023 blueprint for research: Cancer control and supportive care. Pediatr Blood Cancer. 2023 09; 70 Suppl 6:e30568. View Abstract
  11. A single-institution pediatric and young adult interventional oncology collaborative: Novel therapeutic options for relapsed/refractory solid tumors. Cancer Med. 2023 06; 12(12):13300-13308. View Abstract
  12. Consensus-Based Best Practice Guidelines for the Management of Spinal Deformity and Associated Tumors in Pediatric Neurofibromatosis Type 1: Screening and Surveillance, Surgical Intervention, and Medical Therapy. J Pediatr Orthop. 2023 Aug 01; 43(7):e531-e537. View Abstract
  13. Pediatric central nervous system tumor survivor and caregiver experiences with multidisciplinary telehealth. J Neurooncol. 2023 Mar; 162(1):191-198. View Abstract
  14. Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA. Cancer Discov. 2023 03 01; 13(3):654-671. View Abstract
  15. Management of neurofibromatosis type 1-associated plexiform neurofibromas. Neuro Oncol. 2022 11 02; 24(11):1827-1844. View Abstract
  16. MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus. Neuro Oncol. 2022 11 02; 24(11):1845-1856. View Abstract
  17. Consensus Recommendations for Managing Childhood Cancer Survivors at Risk for Stroke After Cranial Irradiation: A Delphi Study. Neurology. 2022 10 18; 99(16):e1755-e1766. View Abstract
  18. Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: An international consensus recommendation. Genet Med. 2022 09; 24(9):1967-1977. View Abstract
  19. Awareness and agreement with neurofibromatosis care guidelines among U.S. neurofibromatosis specialists. Orphanet J Rare Dis. 2022 02 10; 17(1):44. View Abstract
  20. Practical guidance for telemedicine use in neuro-oncology. Neurooncol Pract. 2022 Apr; 9(2):91-104. View Abstract
  21. Recommendations for Social Skills End Points for Clinical Trials in Neurofibromatosis Type 1. Neurology. 2021 08 17; 97(7 Suppl 1):S73-S80. View Abstract
  22. Long-term neurocognitive and quality of life outcomes in survivors of pediatric hematopoietic cell transplant. J Cancer Surviv. 2022 06; 16(3):696-704. View Abstract
  23. Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation. Genet Med. 2021 08; 23(8):1506-1513. View Abstract
  24. Neurotoxic Effects of Childhood Cancer Therapy and Its Potential Neurocognitive Impact. J Clin Oncol. 2021 06 01; 39(16):1752-1765. View Abstract
  25. Surveillance for subsequent neoplasms of the CNS for childhood, adolescent, and young adult cancer survivors: a systematic review and recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol. 2021 05; 22(5):e196-e206. View Abstract
  26. Outcomes after first relapse of childhood intracranial ependymoma. Pediatr Blood Cancer. 2021 08; 68(8):e28930. View Abstract
  27. The impact of the COVID-19 pandemic on neurofibromatosis clinical care and research. Orphanet J Rare Dis. 2021 02 01; 16(1):61. View Abstract
  28. Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial. Nat Med. 2021 01; 27(1):165-173. View Abstract
  29. Are Some Randomized Clinical Trials Impossible? J Pediatr Orthop. 2021 Jan; 41(1):e90-e93. View Abstract
  30. Visual outcomes following everolimus targeted therapy for neurofibromatosis type 1-associated optic pathway gliomas in children. Pediatr Blood Cancer. 2021 04; 68(4):e28833. View Abstract
  31. Visual field outcomes in children treated for neurofibromatosis type 1-associated optic pathway gliomas: a multicenter retrospective study. J AAPOS. 2020 12; 24(6):349.e1-349.e5. View Abstract
  32. A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1-associated pediatric low-grade glioma: a Neurofibromatosis Clinical Trials Consortium study. Neuro Oncol. 2020 10 14; 22(10):1527-1535. View Abstract
  33. Neuro-Oncology Training for the Child Neurology Resident. J Child Neurol. 2021 01; 36(1):79-82. View Abstract
  34. Assessment of provider perspectives on otoprotection research for children and adolescents: A Children's Oncology Group Cancer Control and Supportive Care Committee survey. Pediatr Blood Cancer. 2020 11; 67(11):e28647. View Abstract
  35. Novel predictive scoring system for morbid hypothalamic obesity in patients with pediatric craniopharyngioma. Childs Nerv Syst. 2021 02; 37(2):403-410. View Abstract
  36. Trametinib for the treatment of recurrent/progressive pediatric low-grade glioma. J Neurooncol. 2020 Sep; 149(2):253-262. View Abstract
  37. Prescription Psychoactive Medication Use in Adolescent Survivors of Childhood Cancer and Association With Adult Functional Outcomes. JNCI Cancer Spectr. 2020 Oct; 4(5):pkaa057. View Abstract
  38. Late morbidity and mortality in adult survivors of childhood glioma with neurofibromatosis type 1: report from the Childhood Cancer Survivor Study. Genet Med. 2020 11; 22(11):1794-1802. View Abstract
  39. The Use of MEK Inhibitors in Neurofibromatosis Type 1-Associated Tumors and Management of Toxicities. Oncologist. 2020 07; 25(7):e1109-e1116. View Abstract
  40. Genomics of MPNST (GeM) Consortium: Rationale and Study Design for Multi-Omic Characterization of NF1-Associated and Sporadic MPNSTs. Genes (Basel). 2020 04 02; 11(4). View Abstract
  41. Natural History and Management of Incidentally Discovered Focal Brain Lesions Indeterminate for Tumor in Children. Neurosurgery. 2020 03 01; 86(3):357-365. View Abstract
  42. Visual spatial learning outcomes for clinical trials in neurofibromatosis type 1. Ann Clin Transl Neurol. 2020 02; 7(2):245-249. View Abstract
  43. Optimizing Postoperative Surveillance of Pediatric Low-Grade Glioma Using Tumor Behavior Patterns. Neurosurgery. 2020 02 01; 86(2):288-297. View Abstract
  44. Cognition, ADHD Symptoms, and Functional Impairment in Children and Adolescents With Neurofibromatosis Type 1. J Atten Disord. 2021 06; 25(8):1177-1186. View Abstract
  45. Reproducibility of cognitive endpoints in clinical trials: lessons from neurofibromatosis type 1. Ann Clin Transl Neurol. 2019 12; 6(12):2555-2565. View Abstract
  46. Clinical spectrum of individuals with pathogenic NF1 missense variants affecting p.Met1149, p.Arg1276, and p.Lys1423: genotype-phenotype study in neurofibromatosis type 1. Hum Mutat. 2020 01; 41(1):299-315. View Abstract
  47. Multicenter, Prospective, Phase II and Biomarker Study of High-Dose Bevacizumab as Induction Therapy in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannoma. J Clin Oncol. 2019 12 10; 37(35):3446-3454. View Abstract
  48. The Impact of Intraoperative Electrocorticography on Seizure Outcome After Resection of Pediatric Brain Tumors: A Cohort Study. Neurosurgery. 2019 09 01; 85(3):375-383. View Abstract
  49. Sixty years single institutional experience with pediatric craniopharyngioma: between the past and the future. Childs Nerv Syst. 2020 02; 36(2):291-296. View Abstract
  50. Health Supervision for Children With Neurofibromatosis Type 1. Pediatrics. 2019 05; 143(5). View Abstract
  51. From process to progress-2017 International Conference on Neurofibromatosis 1, Neurofibromatosis 2 and Schwannomatosis. Am J Med Genet A. 2019 06; 179(6):1098-1106. View Abstract
  52. A Review of Chronic Leukoencephalopathy among Survivors of Childhood Cancer. Pediatr Neurol. 2019 12; 101:2-10. View Abstract
  53. Correction: Expanding the clinical phenotype of individuals with a 3-bp in-frame deletion of the NF1 gene (c.2970_2972del): an update of genotype-phenotype correlation. Genet Med. 2019 03; 21(3):764-765. View Abstract
  54. Pain affect disrupted in children with posterior cerebellar tumor resection. Ann Clin Transl Neurol. 2019 02; 6(2):344-354. View Abstract
  55. Risk factors for chemotherapy-induced nausea in pediatric patients receiving highly emetogenic chemotherapy. Pediatr Blood Cancer. 2019 04; 66(4):e27584. View Abstract
  56. Identifying clinical practice guidelines for the supportive care of children with cancer: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2019 01; 66(1):e27471. View Abstract
  57. Expanding the clinical phenotype of individuals with a 3-bp in-frame deletion of the NF1 gene (c.2970_2972del): an update of genotype-phenotype correlation. Genet Med. 2019 04; 21(4):867-876. View Abstract
  58. Peripheral neuropathy in children and adolescents treated for cancer. Lancet Child Adolesc Health. 2018 10; 2(10):744-754. View Abstract
  59. The management of childhood cancer survivors at risk for stroke: A Delphi survey of regional experts. Pediatr Blood Cancer. 2018 12; 65(12):e27394. View Abstract
  60. 2016 Children's Tumor Foundation conference on neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosis. Am J Med Genet A. 2018 05; 176(5):1258-1269. View Abstract
  61. The Effectiveness of a Hospital-Based School Liaison Program: A Comparative Study of Parental Perception of School Supports for Children With Pediatric Cancer and Neurofibromatosis Type 1. J Pediatr Oncol Nurs. 2018 Jul/Aug; 35(4):276-286. View Abstract
  62. Children's at Home: Pilot Study Assessing Dedicated Social Media for Parents of Adolescents with Neurofibromatosis Type 1. J Genet Couns. 2018 04; 27(2):505-517. View Abstract
  63. Longitudinal assessment of late-onset neurologic conditions in survivors of childhood central nervous system tumors: a Childhood Cancer Survivor Study report. Neuro Oncol. 2018 01 10; 20(1):132-142. View Abstract
  64. Genotype-Phenotype Correlation in NF1: Evidence for a More Severe Phenotype Associated with Missense Mutations Affecting NF1 Codons 844-848. Am J Hum Genet. 2018 01 04; 102(1):69-87. View Abstract
  65. Acupressure bands do not improve chemotherapy-induced nausea control in pediatric patients receiving highly emetogenic chemotherapy: A single-blinded, randomized controlled trial. Cancer. 2018 03 15; 124(6):1188-1196. View Abstract
  66. School liaison program supporting children with neurofibromatosis type 1: a model of care for children with chronic disease. Genet Med. 2018 07; 20(7):785-788. View Abstract
  67. Liver Failure as the Presentation of Ornithine Transcarbamylase Deficiency in a 13-Month-Old Female. JIMD Rep. 2018; 40:17-22. View Abstract
  68. Visual and ocular motor outcomes in children with posterior fossa tumors. J AAPOS. 2017 Oct; 21(5):375-379. View Abstract
  69. Brain tumors and epileptic spasms: Natural history and outcomes. Epilepsy Behav. 2017 10; 75:25-28. View Abstract
  70. Rethinking childhood ependymoma: a retrospective, multi-center analysis reveals poor long-term overall survival. J Neurooncol. 2017 Oct; 135(1):201-211. View Abstract
  71. Long-term neurologic health and psychosocial function of adult survivors of childhood medulloblastoma/PNET: a report from the Childhood Cancer Survivor Study. Neuro Oncol. 2017 05 01; 19(5):689-698. View Abstract
  72. The path forward: 2015 International Children's Tumor Foundation conference on neurofibromatosis type 1, type 2, and schwannomatosis. Am J Med Genet A. 2017 Jun; 173(6):1714-1721. View Abstract
  73. A 15-Month-Old Girl Presenting With Clitoromegaly and a Chest Mass. Semin Pediatr Neurol. 2018 07; 26:128-131. View Abstract
  74. A 15-Year-Old Girl With Sudden Onsent Reversible Neurologic Symptoms After Cranial Irradiation for Medulloblastoma. Semin Pediatr Neurol. 2018 07; 26:124-127. View Abstract
  75. Phase II trial of pegylated interferon alfa-2b in young patients with neurofibromatosis type 1 and unresectable plexiform neurofibromas. Neuro Oncol. 2017 02 01; 19(2):289-297. View Abstract
  76. Analysis of copy number variants in 11 pairs of monozygotic twins with neurofibromatosis type 1. Am J Med Genet A. 2017 Mar; 173(3):647-653. View Abstract
  77. Randomized placebo-controlled study of lovastatin in children with neurofibromatosis type 1. Neurology. 2016 Dec 13; 87(24):2575-2584. View Abstract
  78. Neurocognitive outcomes in neurofibromatosis clinical trials: Recommendations for the domain of attention. Neurology. 2016 Aug 16; 87(7 Suppl 1):S21-30. View Abstract
  79. Clinical Trial of the Protein Farnesylation Inhibitors Lonafarnib, Pravastatin, and Zoledronic Acid in Children With Hutchinson-Gilford Progeria Syndrome. Circulation. 2016 Jul 12; 134(2):114-25. View Abstract
  80. Long-term visual outcomes of optic pathway gliomas in pediatric patients without neurofibromatosis type 1. J Neurooncol. 2016 08; 129(1):173-8. View Abstract
  81. Vitamin B12 Deficiency Presenting with Neurological Dysfunction in an Adolescent. Pediatr Neurol. 2016 09; 62:66-70. View Abstract
  82. Myxopapillary ependymomas in children: imaging, treatment and outcomes. J Neurooncol. 2016 Jan; 126(1):165-174. View Abstract
  83. MITF is a critical regulator of the carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) in malignant melanoma. Pigment Cell Melanoma Res. 2015 Nov; 28(6):736-40. View Abstract
  84. CEACAM1-4L Promotes Anchorage-Independent Growth in Melanoma. Front Oncol. 2015; 5:234. View Abstract
  85. Neurocutaneous Syndromes and Brain Tumors. J Child Neurol. 2016 10; 31(12):1399-411. View Abstract
  86. Bacillus cereus Cerebral Abscess During Induction Chemotherapy for Childhood Acute Leukemia. J Pediatr Hematol Oncol. 2015 Oct; 37(7):568-9. View Abstract
  87. Incidence, risk factors, and longitudinal outcome of seizures in long-term survivors of pediatric brain tumors. Epilepsia. 2015 Oct; 56(10):1599-604. View Abstract
  88. Risk of seizures in children with tectal gliomas. Epilepsia. 2015 Sep; 56(9):e139-42. View Abstract
  89. CEACAM1-3S Drives Melanoma Cells into NK Cell-Mediated Cytolysis and Enhances Patient Survival. Cancer Res. 2015 May 01; 75(9):1897-907. View Abstract
  90. Hutchinson-Gilford progeria syndrome. Handb Clin Neurol. 2015; 132:249-64. View Abstract
  91. Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a neurofibromatosis Clinical Trials Consortium phase II study. Neuro Oncol. 2015 Apr; 17(4):596-603. View Abstract
  92. Update from the 2013 International Neurofibromatosis Conference. Am J Med Genet A. 2014 Dec; 164A(12):2969-78. View Abstract
  93. Developing interventions for cancer-related cognitive dysfunction in childhood cancer survivors. J Natl Cancer Inst. 2014 Aug; 106(8). View Abstract
  94. Recurrence after gross-total resection of low-grade pediatric brain tumors: the frequency and timing of postoperative imaging. J Neurosurg Pediatr. 2014 Oct; 14(4):356-64. View Abstract
  95. Gender as a disease modifier in neurofibromatosis type 1 optic pathway glioma. Ann Neurol. 2014 May; 75(5):799-800. View Abstract
  96. Cerebellar mutism after posterior fossa tumor resection: case discussion and recommendations for psychoeducational intervention. J Pediatr Oncol Nurs. 2014 Mar-Apr; 31(2):78-83. View Abstract
  97. Long-term outcome of 4,040 children diagnosed with pediatric low-grade gliomas: an analysis of the Surveillance Epidemiology and End Results (SEER) database. Pediatr Blood Cancer. 2014 Jul; 61(7):1173-9. View Abstract
  98. CTF meeting 2012: Translation of the basic understanding of the biology and genetics of NF1, NF2, and schwannomatosis toward the development of effective therapies. Am J Med Genet A. 2014 Mar; 164A(3):563-78. View Abstract
  99. Functional outcome measures for NF1-associated optic pathway glioma clinical trials. Neurology. 2013 Nov 19; 81(21 Suppl 1):S15-24. View Abstract
  100. Neurologic features of Hutchinson-Gilford progeria syndrome after lonafarnib treatment. Neurology. 2013 Jul 30; 81(5):427-30. View Abstract
  101. Predictors of neoplastic disease in children with isolated pituitary stalk thickening. Pediatr Blood Cancer. 2013 Oct; 60(10):1630-5. View Abstract
  102. Calvarial defects and skeletal dysplasia in patients with neurofibromatosis Type 1. J Neurosurg Pediatr. 2013 Apr; 11(4):410-6. View Abstract
  103. Moyamoya syndrome associated with neurofibromatosis Type 1: perioperative and long-term outcome after surgical revascularization. J Neurosurg Pediatr. 2013 Apr; 11(4):417-25. View Abstract
  104. Children's Oncology Group's 2013 blueprint for research: cancer control and supportive care. Pediatr Blood Cancer. 2013 Jun; 60(6):1027-30. View Abstract
  105. Prevalence and predictors of prescription psychoactive medication use in adult survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J Cancer Surviv. 2013 Mar; 7(1):104-14. View Abstract
  106. Imaging characteristics of cerebrovascular arteriopathy and stroke in Hutchinson-Gilford progeria syndrome. AJNR Am J Neuroradiol. 2013 May; 34(5):1091-7. View Abstract
  107. Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci U S A. 2012 Oct 09; 109(41):16666-71. View Abstract
  108. Academic women faculty: are they finding the mentoring they need? J Womens Health (Larchmt). 2012 Nov; 21(11):1201-8. View Abstract
  109. Morning glory disc anomaly in association with ipsilateral optic nerve glioma. Arch Ophthalmol. 2012 Aug; 130(8):1082-3. View Abstract
  110. 168 Moyamoya Syndrome Associated with Neurofibromatosis Type 1 in Children. Neurosurgery. 2012 Aug 01; 71(2):E566. View Abstract
  111. Psychoactive medication use and neurocognitive function in adult survivors of childhood cancer: a report from the Childhood Cancer Survivor study. Pediatr Blood Cancer. 2013 Mar; 60(3):486-93. View Abstract
  112. Sleep dysfunction in long term survivors of craniopharyngioma. J Neurooncol. 2012 Jul; 108(3):543-9. View Abstract
  113. Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis. Neuro Oncol. 2012 Jun; 14(6):790-7. View Abstract
  114. Craniofacial abnormalities in Hutchinson-Gilford progeria syndrome. AJNR Am J Neuroradiol. 2012 Sep; 33(8):1512-8. View Abstract
  115. [18F]-Fluorodeoxyglucose positron emission tomography in children with neurofibromatosis type 1 and plexiform neurofibromas: correlation with malignant transformation. J Neurooncol. 2012 Jul; 108(3):469-75. View Abstract
  116. Introduction. Neurologic sequelae of cancer in children. Semin Pediatr Neurol. 2012 Mar; 19(1):1-2. View Abstract
  117. Neurocognitive dysfunction in survivors of childhood brain tumors. Semin Pediatr Neurol. 2012 Mar; 19(1):35-42. View Abstract
  118. Discovery of asymptomatic moyamoya arteriopathy in pediatric syndromic populations: radiographic and clinical progression. Neurosurg Focus. 2011 Dec; 31(6):E6. View Abstract
  119. Neuro-oncology training for the child neurology resident. Semin Pediatr Neurol. 2011 Jun; 18(2):120-2. View Abstract
  120. Long-term clinical outcomes following treatment of childhood craniopharyngioma. Pediatr Blood Cancer. 2011 Jul 01; 56(7):1120-6. View Abstract
  121. Association of rapidly progressive moyamoya syndrome with bevacizumab treatment for glioblastoma in a child with neurofibromatosis type 1. J Child Neurol. 2011 Feb; 26(2):228-30. View Abstract
  122. Germinoma with malignant transformation to nongerminomatous germ cell tumor. J Neurosurg Pediatr. 2010 Sep; 6(3):295-8. View Abstract
  123. Clinicopathologic study of glioblastoma in children with neurofibromatosis type 1. Pediatr Blood Cancer. 2010 Jul 01; 54(7):890-6. View Abstract
  124. Pilot study of a novel computerized task to assess spatial learning in children and adolescents with neurofibromatosis type 1. J Child Neurol. 2010 Oct; 25(10):1195-202. View Abstract
  125. Neurologic sequelae of brain tumors in children. J Child Neurol. 2009 Nov; 24(11):1446-54. View Abstract
  126. Algal lipid bodies: stress induction, purification, and biochemical characterization in wild-type and starchless Chlamydomonas reinhardtii. Eukaryot Cell. 2009 Dec; 8(12):1856-68. View Abstract
  127. A prospective, blinded analysis of A-PROTEIN (recoverin or CAR protein) levels in pediatric patients with central nervous system tumors. Pediatr Blood Cancer. 2009 Sep; 53(3):343-7. View Abstract
  128. Medical, psychological, cognitive and educational late-effects in pediatric low-grade glioma survivors treated with surgery only. Pediatr Blood Cancer. 2009 Sep; 53(3):417-23. View Abstract
  129. Intensive multimodality treatment for children with newly diagnosed CNS atypical teratoid rhabdoid tumor. J Clin Oncol. 2009 Jan 20; 27(3):385-9. View Abstract
  130. CNS relapse of acute myelogenous leukemia masquerading as pseudotumor cerebri. Pediatr Neurol. 2008 Nov; 39(5):355-7. View Abstract
  131. Outcome of pediatric pineoblastoma after surgery, radiation and chemotherapy. J Neurooncol. 2008 Aug; 89(1):89-95. View Abstract
  132. Gender differences in research grant applications and funding outcomes for medical school faculty. J Womens Health (Larchmt). 2008 Mar; 17(2):207-14. View Abstract
  133. "The choking game": self-induced hypoxia presenting as recurrent seizurelike events. Epilepsy Behav. 2008 Apr; 12(3):486-8. View Abstract
  134. Inherited disorders as a risk factor and predictor of neurodevelopmental outcome in pediatric cancer. Dev Disabil Res Rev. 2008; 14(3):229-37. View Abstract
  135. Brainstem lesions in neurofibromatosis type 1. Neurosurgery. 2007 Oct; 61(4):762-6; discussion 766-7. View Abstract
  136. Moyamoya following cranial irradiation for primary brain tumors in children. Neurology. 2007 Mar 20; 68(12):932-8. View Abstract
  137. Extracranial metastases of glioblastoma in a child: case report and review of the literature. J Pediatr Hematol Oncol. 2007 Mar; 29(3):190-4. View Abstract
  138. Molecular genetics of pediatric central nervous system tumors. Curr Oncol Rep. 2006 Nov; 8(6):423-9. View Abstract
  139. Phase II study of thalidomide and radiation in children with newly diagnosed brain stem gliomas and glioblastoma multiforme. J Neurooncol. 2007 Mar; 82(1):95-101. View Abstract
  140. Transverse myelitis after therapy for primitive neuroectodermal tumors. Pediatr Neurol. 2006 Aug; 35(2):122-5. View Abstract
  141. Craniopharyngioma therapy: long-term effects on hypothalamic function. Neurologist. 2005 Jan; 11(1):55-60. View Abstract
  142. Electroencephalographic correlate of juvenile Huntington's disease. J Child Neurol. 2004 Jul; 19(7):541-3. View Abstract
  143. Research during pediatric residency: predictors and resident-determined influences. Acad Med. 2003 Dec; 78(12):1253-8. View Abstract
  144. Pediatric brain tumors. Neurol Clin. 2003 Nov; 21(4):897-913. View Abstract
  145. Transient global amnesia in a young adult with cyanotic heart disease. Pediatr Neurol. 2003 Oct; 29(4):334-6. View Abstract
  146. Expression of voltage-activated chloride currents in acute slices of human gliomas. Neuroscience. 1998 Apr; 83(4):1161-73. View Abstract
  147. Cell cycle-dependent expression of a glioma-specific chloride current: proposed link to cytoskeletal changes. Am J Physiol. 1997 10; 273(4):C1290-7. View Abstract
  148. Biophysical and pharmacological characterization of chloride currents in human astrocytoma cells. Am J Physiol. 1996 May; 270(5 Pt 1):C1511-21. View Abstract
  149. Human astrocytoma cells express a unique chloride current. Neuroreport. 1996 Apr 10; 7(5):1020-4. View Abstract
  150. Human astrocytoma cells express a unique chloride current. Neuroreport. 1995 Dec 29; 7(1):343-7. View Abstract
  151. Astrocyte Na+ channels are required for maintenance of Na+/K(+)-ATPase activity. J Neurosci. 1994 May; 14(5 Pt 1):2464-75. View Abstract

Contact Nicole Ullrich

Print Profile